Parkinson's Disease Quality of Life (PDQUALIF) - symptoms 7days compare 6-months scale

General Details:

Name:
Parkinson's Disease Quality of Life (PDQUALIF) - symptoms 7days compare 6-months scale
Steward:
NINDS
Definition:
Rating scale for the Parkinson's symptoms in past 7 days compared to 6 months ago as part of Parkinson's Disease Quality of Life (PDQUALIF) form
Registration Status:
Qualified

Permissible Values:

Data Type:
Value List
Unit of Measure:
Ids:
Value Code Name Code Code System Code Description
Much better Much better Much better
Somewhat better Somewhat better Somewhat better
About the same About the same About the same
Somewhat worse Somewhat worse Somewhat worse
Much Worse Much Worse Much Worse

Designations:

Designation:
Parkinson's Disease Quality of Life (PDQUALIF) - symptoms 7days compare 6-months scale
Tags:

Designations:

Definition:
Rating scale for the Parkinson's symptoms in past 7 days compared to 6 months ago as part of Parkinson's Disease Quality of Life (PDQUALIF) form
Tags:

Reference Documents:

ID:
Title:
URI:
Provider Org:
Language Code:
Document:
PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237.

Identifiers:

Source:
NLM
Id:
1m3_BEZoQaq
Version:
3.1
Source:
NINDS
Id:
C17393
Version:
3
Source:
BRICS Variable Name
Id:
PDQUALIFSymp7DComp6MScale
Version: